Wuhan Institute of Biological Products

R&D center of China National Pharmaceutical Group in Wuhan

You can help expand this article with text translated from the corresponding article in Chinese. (August 2021) Click [show] for important translation instructions.

View a machine-translated version of the Chinese article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 343 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Chinese Wikipedia article at [[:zh:武汉生物制品研究所]]; see its history for attribution.
You may also add the template {{Translated|zh|武汉生物制品研究所}} to the talk page.
For more guidance, see Wikipedia:Translation.

The Wuhan Institute of Biological Products (WIBP Chinese: 武汉生物制品研究所) or Wuhan Institute of Biology for short is a subsidiary of China National Pharmaceutical Group, a Chinese state-owned enterprise commonly known as Sinopharm.^[1] The institute integrates production, education, research, and marketing, and operates one of the main production facilities for biological products in China, with over 1,000 employees. The commercial arm of the institute operates a wholly owned subsidiary called Wuhan Zhongsheng Yujin Biomedical, which is primarily focused on the production distribution of blood products including human albumin, human immune globulin and tetanus immune globulin. The educational arm of the institute confers Master's degrees and runs doctoral and postdoctoral programs in biotechnology related fields. The institute was established in September 1950 in Wuchang District, moving in 2016 to the Zhengdian Gold Industrial Park in Jiangxia District, next to the Wuhan Institute of Virology, with which it collaborates closely.^[2]^[3]

Divisions

National Engineering Technology Research Center for Combined Vaccines^{[citation needed]}

References

^ "Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 bln doses". Reuters. June 1, 2021.
^ Philippidis, Alex (May 18, 2020). "Sinopharm Group (Wuhan Institute of Biological Products) and Chinese Academy of Sciences (Wuhan Institute of Virology)".
^ "Two COVID-19 vaccines approved in China in less than 24 hours". www.bioworld.com.